噻托溴铵联合舒利迭对慢性阻塞性肺疾病患者肺功能及生活质量的影响

The Effect of Combined Use of Tiotropium Bromide and Suletide on Lung Function and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

目的探讨噻托溴铵与舒利迭联合用药对慢性阻塞性肺疾病患者肺功能及生活质量的影响.方法选取2020年2月—2022年2月我院收治的100例慢性阻塞性肺疾病患者为研究对象,采用随机数字表法将其分为联合用药组和单独用药组,各50例.单独用药组采用舒利迭治疗,联合用药组联合应用噻托溴铵与舒利迭治疗.对比两组气流受限程度﹑运动耐力﹑肺功能﹑病情程度﹑呼吸困难程度﹑呼吸问题﹑临床疗效﹑动脉血气分析﹑生活质量﹑急性发作次数﹑医疗费用﹑不良反应发生情况.结果用药后,联合用药组患者6 min步行距离(6MWD)远于单独用药组,第1秒用力呼气容积占预计值百分比﹑第1秒用力呼气容积(FEV_(1))及其百分比﹑用力肺活量(FVC)及FEV_(1)/FVC﹑深吸气量均大于单独用药组,功能残气量﹑慢性阻塞性肺疾病病情评估测试评分﹑改良英国MRC呼吸困难指数评分﹑圣乔治医院呼吸问题调查问卷评分均低于单独用药组,组间差异有统计学意义(P<0.05).联合用药组患者的治疗总有效率92.00%高于单独用药组的68.00%,差异有统计学意义(P<0.05).用药后,联合用药组患者的动脉血氧分压﹑健康责任评分﹑营养评分﹑运动评分﹑人际关系评分﹑应对压力评分﹑自我实现评分均高于单独用药组,二氧化碳分压低于单独用药组,组间差异有统计学意义(P<0.05).联合用药组患者的急性发作次数少于单独用药组,差异有统计学意义(P<0.05);两组患者的医疗费用比较,差异无统计学意义(P>0.05).两组患者的不良反应发生率比较,差异无统计学意义(P>0.05).结论采用噻托溴铵与舒利迭联合用药治疗慢性阻塞性肺疾病较舒利迭单独用药对患者肺功能及生活质量的改善作用更明显.

Objective To investigate the effects of combined use of tiotropium bromide and suletide on lung function and quality of life in patients with chronic obstructive pulmonary disease.Methods 100 patients with chronic obstructive pulmonary disease admitted to our hospital from February 2020 to February 2022 were selected as the research subjects,and they were randomly divided into a combination therapy group and a single therapy group using a random number table method,with 50 cases in each group.The monotherapy group was treated with suletide,while the combination therapy group was treated with a combination of tiotropium bromide and suletide..The degrees of airflow restriction,exercise endurance,pulmonary function,disease severity,dyspnea,respiratory problems,clinical efficacy,arterial blood gas analysis,quality of life,number of acute attacks,medical costs,and adverse reactions were statistically analyzed in the two groups.Results After medication,patients in the combination therapy group had a longer 6-minute walking distance than those in the monotherapy group,and the percentage of forced expiratory volume in the first second to the expected value,forced expiratory volume in the first second(FEV_(1))and its percentage,forced vital capacity(FVC)and FEV_(1)/FVC,and deep inspiratory volume were all higher than those in the monotherapy group,and the functional residual gas volume,Chronic Obstructive Pulmonary Disease Assessment Test Score,Modified British MRC Dyspnea Index Score,and the Respiratory Questionnaire Scores of St.George's Hospital were lower than those of the monotherapy group,and there was a statistically significant difference between the groups(P<0.05).The total effective rate of patients in the combination therapy group was 92.00%,higher than 68.00%in the monotherapy group,and the difference was statistically significant(P<0.05).After medication,the arterial oxygen pressure,health responsibility score,nutritional score,exercise score,interpersonal relationship score,coping pressure score,and self actualization score of patients in the combination therapy group were higher than those in the monotherapy group,while the carbon dioxide pressure was lower than that in the monotherapy group,and the differences between the groups were statistically significant(P<0.05).The number of acute attacks in the combination therapy group was lower than that in the monotherapy group,and the difference was statistically significant(P<0.05);There was no statistically significant difference in medical expenses between the two groups of patients(P>0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05)Conclusion In the treatment of chronic obstructive pulmonary disease,the combination of tiotropium bromide and suletide is more effective in improving lung function and quality of life compared to suletide alone.